Skip to main content
BET bromodomain inhibition of MYC-amplified medulloblastoma.
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma.
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption.
Promising therapeutic targets in neuroblastoma.
Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.
Targeted therapy for BRAFV600E malignant astrocytoma.
Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.
Principles and current strategies for targeting autophagy for cancer treatment.